多价细菌疫苗预防原发性肾病综合征患儿医院感染的临床研究

目的　探讨多价细菌疫苗—兰菌净预防原发性肾病综合征 (PNS)患儿医院感染的疗效。方法　对 46例PNS患儿采用随机对照方法观察比较兰菌净治疗组和对照组的感染率、治疗前后T细胞亚群、免疫球蛋白及尿蛋白量下降程度的变化。结果治疗后 ,治疗组的医院感染率为 9.1% ,对照组为 3 7.5 % ,两组比较差异有显著意义 (P <0 .0 5 ) ;治疗组的T细胞亚群、免疫球蛋白等免疫指标比对照组有明显改善 ,CD3、CD4、IgG、IgA增高 (P <0 .0 1) ,CD8降低 ,CD4 CD8比值增高 (P <0 .0 5 ) ;而 2 4h尿蛋白量在治疗后有不同程度下降 ,但两组下降程度无差异 (P >0 .0 5 )。结论　兰菌净可明显降低PNS患儿的医院感染率。

The Clinical Research on Using Polyvalent Bacterial Vaccine to Prevent the Nosocomial Infection of Children With Primary Nephritic Syndrome

Objectives To Observe the effect of oral polyvalent bacterial vaccine Lantigen B on preventing nosocomial infection of children with primary nephritic syndrome(PNS). Methods 46 PNS inpatients were divided into Lantigen B group (treated with Lantigen B) and control group randomly. The nosocomial infection rate, the decrease of albuminuria, the levels of T cell subset and immunoglobulin were observed in two groups. Results After treatment, the nosocomial infection rate of lantigen B group was 9.1%, and the rate of control group was 37.5%. The difference of nosocomial infection rate in two groups was significant (P<0.05). The differences of levels of T cell subset and immunoglobulin between two groups were significant. In Lantigen B group, the levels of CD3, CD4, IgG, IgA and the ratio of CD4/CD8 increased (P<0.01, or P<0.05), the number of CD8 decreased (P<0.05). The difference of the decrease on urine protein between two groups was insignificant (P>0.05). Conclusion Lantigen B can obviously reduce the nosocomial infection rate of PNS children.